Overactive bladder (OAB)
OAB is a condition that induces a frequent urge to urinate to a degree that negatively impacts one's daily life.
The frequent need to urinate may occur during the day, at night, or throughout the whole day.
When one completely loses control of their bladder, then we are talking about urge incontinence. More than 40% of people with overactive bladder suffer from incontinence. Conversely, about 40% to 70% of urinary incontinence happen due to OAB.
OAB is not life-threatening, but most people with the condition have problems for years. OAB can have a profound effect on one's quality of life. It can severely impact daily activities such as work, travel, interpersonal relationships, physical activity, sexual function, and sleep. Not only do OAB and associated incontinence diminish overall quality of life, but their presence can also create additional health problems. These include increased risk of falls and fractures, urinary tract and skin infections, sleep disturbances, and depression.
In 2020, more than 25.5 million people over 40 years of age will suffer from OAB in the EU's 5 biggest nations. This number includes 9 million people who will suffer from urge incontinence. The average annual direct costs of OAB treatment range from €339 to €890 per patient. The largest costs come with the use of incontinence pads, accounting for an average of 63% of the annual per-patient costs of OAB treatment and management. The total expenses of health care systems across the five countries were estimated at €5.2 billions.
URIS is a product designed for ordinary people which allows them to heal themselves in the comfort of their homes. Thanks to URIS they will not need to spend any more time by traveling or waiting at the doctor's office. The use of this device enables a very simple, convenient, and effective treatment, all thanks to our unique software and patented technology.
Electrical Transcutaneous Nerve Modulation (ETNM) is a neuromodulation method delivered by URIS. This method reduces the symptoms of urge urinary incontinence by more than 50% among 75% of patients.
Non – invasive, Safe, Effective.